ADVANCED LUNG NON-SMALL CELL CARCINOMA
Clinical trials for ADVANCED LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat lung cancer: targeted pill shows promise
Disease control Recruiting nowThis study tests a pill called osimertinib in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors or slow the cancer's growth. About 46 adults with stage IIIB or IV disease, …
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
Common painkiller may help immunotherapy fight lung cancer
Disease control Recruiting nowThis study tests whether adding diclofenac, a common anti-inflammatory painkiller, can help control tumor growth in people with advanced non-small cell lung cancer whose disease is starting to worsen while on immunotherapy alone. About 20 adults with stage III or IV lung cancer w…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New drug combo aims to stop advanced lung cancer growth
Disease control Recruiting nowThis study tests a new drug (MRX-2843) combined with a standard treatment (osimertinib) in people with advanced EGFR-mutant non-small cell lung cancer. The goal is to find the safest dose and see how well the combination works. About 69 participants will take part in this early-p…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New combo targets hard-to-treat lung cancer mutation in early trial
Disease control Recruiting nowThis early-stage trial tests whether combining two drugs, carfilzomib and sotorasib, is safe and effective for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. About 15 adults who have already tried a KRAS-targeting drug will re…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New hope for seniors with lung cancer: immunotherapy with or without chemo?
Disease control Recruiting nowThis study tests whether adding chemotherapy to immunotherapy (pembrolizumab) works better than immunotherapy alone for adults aged 70 and older with advanced non-small cell lung cancer. The goal is to see which approach helps patients live longer and keeps the cancer from growin…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New hope for stubborn lung cancer: drug duo targets STK11 mutation
Disease control Recruiting nowThis study tests a new drug combination (GT103 plus pembrolizumab) in people with advanced or spreading non-small cell lung cancer that has a specific gene change called STK11. The goal is to see if the combo can shrink tumors or slow the cancer better than current options. About…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 06, 2026 16:03 UTC
-
Morning vs. afternoon: can timing boost cancer immunotherapy?
Symptom relief Recruiting nowThis study looks at whether getting immunotherapy in the morning or afternoon changes how well it fights advanced or metastatic solid tumors. Researchers believe the body's internal clock (circadian rhythm) might affect immune response. About 160 adults with certain cancers like …
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE4 • Sponsor: OHSU Knight Cancer Institute • Aim: Symptom relief
Last updated May 16, 2026 23:47 UTC
-
Scientists seek to unlock the secrets of cancer wasting
Knowledge-focused Recruiting nowThis study looks at 800 people with advanced lung, pancreatic, or colorectal cancer to find different types of cancer-related weight and muscle loss (cachexia). Researchers will track symptoms, physical function, and blood markers over time. The goal is to identify distinct subty…
Matched conditions: ADVANCED LUNG NON-SMALL CELL CARCINOMA
Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated May 13, 2026 16:01 UTC